Human inositol monophosphatase H1

Abstract

Human inositol monophosphatase H1 polynucleotide and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptide by recombinant techniques and utilizing such polypeptide for therapeutic purposes, for example, screening and designing compounds capable of inhibiting hIMP-H1 and mapping genetic diseases are disclosed. Further disclosed are antibodies against hIMP-H1 polypeptides and methods for producing such antibodies and utilizing such antibodies for therapeutic or diagnostic purposes. Also disclosed is antagonists against such polypeptide along with procedures for using such antagonists for therapeutic purposes, for example, for treating psychotic and depressive disorders. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention are also disclosed.

What is claimed is:  
     
         1 . An isolated polynucleotide comprising a member selected from the group consisting of: 
 (a) a polynucleotide encoding the polypeptide comprising amino acid 1 to amino acid 265 as set forth in SEQ ID NO:2;    (b) a polynucleotide capable of hybridizing to and which is at least 70% identical to the polynucleotide of (a); and    (c) a polynucleotide fragment of the polynucleotide of (a) or (b).    
     
     
         2 . The polynucleotide of  claim 1  wherein the polynucleotide is DNA.  
     
     
         3 . The polynucleotide of  claim 1  wherein the polynucleotide is RNA.  
     
     
         4 . The polynucleotide of  claim 1  wherein the polynucleotide is genomic DNA.  
     
     
         5 . The polynucleotide of  claim 2  which encodes the polypeptide comprising amino acid 1 to 265 of SEQ ID NO:2.  
     
     
         6 . An isolated polynucleotide comprising a member selected from the group consisting of: 
 (a) a polynucleotide which encodes a mature polypeptide having the amino acid sequence expressed by the DNA contained in ATCC Deposit No. 75753;    (b) a polynucleotide which encodes a mature polypeptide having the amino acid sequence expressed by the DNA contained in ATCC Deposit No. 75753;    (c) a polynucleotide capable of hybridizing to and which is at least 70% identical to the polynucleotide of (a); and    (d) a polynucleotide fragment of the polynucleotide of (a), (b) or (c).    
     
     
         7 . The polynucleotide of  claim 1  comprising the sequence as set forth in SEQ ID No. 1 from nucleotide to nucleotide 798.  
     
     
         8 . The polynucleotide of  claim 1  comprising the sequence as set forth in SEQ ID No. 3 from nucleotide to nucleotide 1313.  
     
     
         9 . A vector containing the DNA of  claim 2 .  
     
     
         10 . A host cell genetically engineered with the vector of  claim 9 .  
     
     
         11 . A process for producing a polypeptide comprising: expressing from the host cell of  claim 10  the polypeptide encoded by said DNA.  
     
     
         12 . A process for producing cells capable of expressing a polypeptide comprising genetically engineering cells with the vector of  claim 9 .  
     
     
         13 . A polypeptide comprising a member selected from the group consisting of (i) a polypeptide having the deduced amino acid sequence of SEQ ID NO:2 and fragments, analogs and derivatives thereof, and (ii) a polypeptide encoded by the cDNA of ATCC Deposit No. 75753 and fragments, analogs and derivatives of said polypeptide.  
     
     
         14 . The polypeptide of  claim 13  wherein the polypeptide comprises amino acid 1 to amino acid 265 of SEQ ID NO:2.  
     
     
         15 . A compound which inhibits activation of the polypeptide of  claim 13 .  
     
     
         16 . A method for the treatment of a patient having need to inhibit a hIMP-HI polypeptide comprising: administering to the patient a therapeutically effective amount of the compound of  claim 13 .  
     
     
         17 . The method of  claim 13  wherein said compound is a polypeptide and said therapeutically effective amount of the polypeptide is administered by providing to the patient DNA encoding said polypeptide and expressing said polypeptide in vivo.  
     
     
         18 . A process for diagnosing a disease or a susceptibility to a disease related to expression of the polypeptide of  claim 13  comprising: 
 determining a mutation in a nucleic acid sequence encoding said polypeptide.  
 
     
     
         19 . A diagnostic process comprising: 
 analyzing for the presence of the polypeptide of  claim 13  in a sample derived from a host.    
     
     
         20 . A process for detecting compounds which inhibit the polypeptide of  claim 13  comprising: 
 contacting a compound with a cell line expressing hIMP-h1 in the presence of inositol monophosphate; and  
 measuring the hydrolysis of inositol monophosphate by hIMP-H1.